Back to Search Start Over

Comparison of Antibody Persistence up to 6 Months after Additional Booster Vaccination with ChAdOx1 nCoV-19 Vaccine

Authors :
Pawita Suwanwattana
May Han
Tanawin Nopsopon
Phanupong Phutrakool
Chatpol Samuthpongtorn
Wannarat Pongpirul
Wisit Prasithsirikul
Krit Pongpirul
Source :
Microbiology Research, Vol 14, Iss 2, Pp 810-818 (2023)
Publication Year :
2023
Publisher :
MDPI AG, 2023.

Abstract

Vaccines are crucial for controlling the COVID-19 pandemic, and booster doses are becoming increasingly important. This study aimed to assess the efficacy of the ChAdOx1 nCoV-19 vaccine from AstraZeneca as a third dose in healthcare workers at different time intervals (one, three, and six months). Two methods to measure immune response—ELISA (EUROIMMUN Medizinische Labordiagnostika AG, Luebeck, Germany) and ELISpot (Mabtech AB, Macka Strand, Sweden)—were used. A total of 170 participants were included in the study. The results showed that while IgG levels decreased at six months compared to levels at one and three months, they were still significantly higher than the baseline. Furthermore, neutralizing levels at three and six months and after the third dose were not significantly different. These findings suggest that the immune response induced by the vaccine was robust and effective for several months. These results have significant implications for public health policymakers, as they provide strong support for booster vaccinations. The ChAdOx1 nCoV-19 vaccine appears to be a reliable option for preventing the spread of COVID-19, and this study provides valuable information for healthcare workers and policymakers in managing the pandemic.

Details

Language :
English
ISSN :
20367481
Volume :
14
Issue :
2
Database :
Directory of Open Access Journals
Journal :
Microbiology Research
Publication Type :
Academic Journal
Accession number :
edsdoj.4ce913d377274f108d15c8caa81d6a37
Document Type :
article
Full Text :
https://doi.org/10.3390/microbiolres14020057